Monitoring the safety of over the counter drugs

David A. Henry; John McEwen

doi:10.1136/bmj.295.6610.1414-b

Monitoring the safety of over the counter drugs

David A. Henry, John McEwen

Research output: Contribution to journal › Letter › Research › peer-review

Original language	English
Pages (from-to)	1414
Number of pages	1
Journal	British Medical Journal (Clinical research ed.)
Volume	295
Issue number	6610
DOIs	https://doi.org/10.1136/bmj.295.6610.1414-b
Publication status	Published - Nov 1987
Externally published	Yes

Access to Document

10.1136/bmj.295.6610.1414-b

Cite this

@article{d22fb41be56f4e59b2c0bd5c9f936a79,

title = "Monitoring the safety of over the counter drugs",

author = "Henry, {David A.} and John McEwen",

note = "Funding Information: Finally, one source of information on adverse reactions not discussed by Dr Volans is the consumer. Most national reporting centres do not encourage large scale self reporting of adverse reactions by patients, and any scheme should be fully evaluated before being recommended for implementation. Anexampleofsuchaprogramme, supported by a grant from the National Health and MedicalResearchCouncilofAustralia, ispresently being tested, and the initial results were presented at the third international conference on pharmaco- epidemiology (A S Mitchell et at). If this system proves successful then it may be particularly suited to the monitoring of non-prescription drugs.",

year = "1987",

month = nov,

doi = "10.1136/bmj.295.6610.1414-b",

language = "English",

volume = "295",

pages = "1414",

journal = "British Medical Journal (Clinical research ed.)",

issn = "0267-0623",

publisher = "BMJ Publishing Group",

number = "6610",

}

TY - JOUR

T1 - Monitoring the safety of over the counter drugs

AU - Henry, David A.

AU - McEwen, John

N1 - Funding Information: Finally, one source of information on adverse reactions not discussed by Dr Volans is the consumer. Most national reporting centres do not encourage large scale self reporting of adverse reactions by patients, and any scheme should be fully evaluated before being recommended for implementation. Anexampleofsuchaprogramme, supported by a grant from the National Health and MedicalResearchCouncilofAustralia, ispresently being tested, and the initial results were presented at the third international conference on pharmaco- epidemiology (A S Mitchell et at). If this system proves successful then it may be particularly suited to the monitoring of non-prescription drugs.

PY - 1987/11

Y1 - 1987/11

UR - http://www.scopus.com/inward/record.url?scp=0023667254&partnerID=8YFLogxK

U2 - 10.1136/bmj.295.6610.1414-b

DO - 10.1136/bmj.295.6610.1414-b

M3 - Letter

C2 - 3121035

AN - SCOPUS:0023667254

SN - 0267-0623

VL - 295

SP - 1414

JO - British Medical Journal (Clinical research ed.)

JF - British Medical Journal (Clinical research ed.)

IS - 6610

ER -

Monitoring the safety of over the counter drugs

Access to Document

Other files and links

Cite this